Strs Ohio Sells 2,400 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Strs Ohio trimmed its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 4.4% in the fourth quarter, Holdings Channel reports. The fund owned 51,700 shares of the medical instruments supplier’s stock after selling 2,400 shares during the quarter. Strs Ohio’s holdings in OraSure Technologies were worth $423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of OSUR. Allspring Global Investments Holdings LLC lifted its stake in shares of OraSure Technologies by 421.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 384,439 shares of the medical instruments supplier’s stock valued at $2,280,000 after buying an additional 310,715 shares during the period. Pacer Advisors Inc. lifted its stake in shares of OraSure Technologies by 122.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier’s stock valued at $19,707,000 after buying an additional 1,323,197 shares during the period. Deutsche Bank AG lifted its stake in shares of OraSure Technologies by 3.1% in the third quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after buying an additional 5,875 shares during the period. Vanguard Group Inc. lifted its stake in shares of OraSure Technologies by 1.2% in the third quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock valued at $32,000,000 after buying an additional 64,367 shares during the period. Finally, Aviva PLC bought a new stake in shares of OraSure Technologies in the third quarter valued at about $580,000. 93.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Evercore ISI reduced their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research note on Thursday, April 4th. StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.38.

OraSure Technologies Stock Up 1.1 %

NASDAQ:OSUR opened at $5.32 on Monday. OraSure Technologies, Inc. has a 12-month low of $4.38 and a 12-month high of $8.45. The firm has a market capitalization of $407.03 million, a PE ratio of 7.39 and a beta of 0.15. The firm has a 50-day moving average price of $6.33 and a 200 day moving average price of $6.81.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.09. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The firm had revenue of $75.88 million during the quarter, compared to analyst estimates of $74.13 million. During the same quarter in the prior year, the business posted $0.21 earnings per share. The company’s quarterly revenue was down 38.3% compared to the same quarter last year. On average, research analysts expect that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.